Evidence map›Paper›PMID 35710293›Full record

ArticleJournal for immunotherapy of cancer2022

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.

Brett Marinelli, Edward Kim, Antonio D'Alessio, Mario Cedillo, Ishan Sinha, Neha Debnath, Masatoshi Kudo, Naoshi Nishida, Anwaar Saeed, Hannah Hildebrand and 16 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. PD1Cancer immunology, immunotherapy : CII · 2025
    Article
  17. Observational
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 5 countries.

Brett MarinelliDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.ORCID 0000-0003-3220-1360
Edward KimDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Antonio D'AlessioDepartment of Surgery and Cancer, Imperial College London, London, UK.
Mario CedilloDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Ishan SinhaDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Neha DebnathDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Masatoshi KudoFaculty of Medicine Hospital, Department of Gastroenterology and Hepatology, Kindai University, Osakasayama, Japan.
Naoshi NishidaFaculty of Medicine Hospital, Department of Gastroenterology and Hepatology, Kindai University, Osakasayama, Japan.
Anwaar SaeedDepartment of Medicine, Division of Clinical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Hannah HildebrandDepartment of Medicine, Division of Clinical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yehia I AbugabalDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anjana PillaiDepartment of Medicine, Section of Gastroenterology, University of Chicago, Chicago, Illinois, USA.
Yi-Hsiang HuangDivision of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0001-5241-5425
Uqba KhanDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, New York, USA.
Mahvish MuzaffarDepartment of Medicine, Division of Hematology and Oncology, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA.
Abdul Rafeh NaqashDepartment of Medicine, Division of Hematology and Oncology, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, Oklahoma, USA.ORCID 0000-0001-7622-720X
Rahul PatelDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Aaron FischmanDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Vivian BishayDivision of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Dominik BettingerDepartment of Medicine II, University of Freiburg Medical Center, Freiburg, Germany.
Max SungDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Celina AngHematology and Oncology, Mount Sinai School of Medicine, New York City, New York, USA.
Myron SchwartzDepartment of Surgery, Recanti/Miller Transplant Institute at the Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0002-3529-0103
Thomas MarronDivision of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York City, New York, USA thomas.marron@mountsinai.org.
Icahn School of Medicine at Mount Sinai · USImperial College London · GBKindai University Hospital · JPThe University of Texas MD Anderson Cancer Center · USUniversity of Kansas Medical Center · USCornell University · USEast Carolina University · USNational Yang Ming Chiao Tung University · TWUniversity of Chicago · USUniversity of Freiburg · DEUniversity of Oklahoma · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes.

methodsFrom a retrospective multicenter dataset of 323 patients treated with ICI, we identified 31 patients who underwent >1 TACE 60 days before or concurrently, with nivolumab at a single center. We derived a propensity score-matched cohort of 104 patients based on Child-Pugh Score, portal vein thrombosis, extrahepatic metastasis and alpha fetoprotein (AFP) who received nivolumab monotherapy. We described overall survival (OS), progression-free survival (PFS), objective responses according to modified RECIST criteria and safety in the multimodal arm in comparison to monotherapy.

resultsOver a median follow-up of 9.3 (IQR 4.0-16.4) months, patients undergoing multimodal immunotherapy with TACE achieved a significantly longer median (95% CI) PFS of 8.8 (6.2-23.2) vs 3.7 (2.7-5.4) months (log-rank 0.15, p<0.01) in the monotherapy group. Multimodal immunotherapy with TACE demonstrated a numerically longer OS compared with ICI monotherapy with a median 35.1 (16.1-Not Evaluable) vs 16.6 (15.7-32.6) months (log-rank 0.41, p=0.12). In the multimodal treatment group, there were three (10%) grade 3 or higher adverse events (AEs) attributed to immunotherapy compared with seven (6.7%) in the matched ICI monotherapy arm. There were no AEs grade 3 or higher attributed to TACE in the multimodal treatment arm. At 3 months following each TACE in the multimodal arm, there was an overall objective response rate of 84%. There were no significant changes in liver functional reserve 1 month following each TACE. Four patients undergoing multimodal treatment were successfully bridged to transplant.

conclusionsTACE can be safely integrated with programmed cell death 1 blockade and may lead to a significant delay in tumor progression and disease downstaging in selected patients.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsHumansNivolumabProgrammed Cell Death 1 ReceptorPropensity ScoreRetrospective StudiesTreatment OutcomeNivolumabProgrammed Cell Death 1 ReceptorCombined Modality TherapyImmunomodulationLiver Neoplasms

Identifiers

PMID35710293
PMCPMC9204420
OpenAlexW4282966628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.